Samsung chief Lee Jae-yong
2021.1.26
Samsung chief failed to appeal his two-and-a-half-year jail sentence
for bribing ex-President Park Geun-hye by the deadline Monday."Lee has humbly accepted
the court's judgment and decided not to appeal," his lawyer said.

It seems Lee concluded any appeal would be pointless since the Supreme Court
already back the case to the Seoul High Court in August 2019.
In a press release, prosecutors said they respects the Seoul High Court's judgment
on Jan. 18, saying their "goal of finding the truth in the corruption and bribery scandal
that brought down Park Geun-hye has been achieved."

Since Lee already served about a year on remand, he has to stay in jail
until July 2022 unless he is released early.


Merck & Co.
ends COVID vaccine program,
cites inferior immune responses

January 25, 2021

Drugmaker Merck & Co. said on Monday it would stop
development of its two COVID-19 vaccines and focus
pandemic research on treatments, with initial data on an
experimental oral antiviral expected by the end of March.

Merck was late to join the race to develop a vaccine
to protect against the coronavirus, which has so far
killed more than 2 million people and continues to surge
in many parts of the world including the United States.

The company will record a pre-tax discontinuation charge
in the fourth quarter for vaccine candidate V591, which
it acquired with the purchase of Austrian vaccine maker
Themis Bioscience, and V590, developed with nonprofit
research organization IAVI, Merck said in a statement.

In early trials, both vaccines generated immune responses
that were inferior to those seen in people who had
recovered from COVID-19 as well as those reported
for other COVID-19 vaccines, the company said.

The announcement is a setback to the fight against
the pandemic and comes a month after Sanofi and
Glaxo Smith Kline delayed launch of their shot to late
2021, underscoring the challenges of developing vaccines
at record speed.

Tens of millions of doses of vaccines from rivals Pfizer Inc
and German partner BioNTech as well as from Moderna Inc
have so far been administered globally.

Johnson & Johnson, AstraZeneca Plc and others are also
racing to develop safe and effective vaccines to protect
against the virus.

Merck said it would focus COVID-19 research and
manufacturing efforts on two investigational medicines:
MK-7110 and MK-4482, which it now calls molnupiravir.

Molnupiravir, which is being developed in collaboration
with Ridgeback Bio, is an oral antiviral being studied
in both hospital and outpatient settings.

Merck said a Phase 2/3 trial of the drug was set to finish
in May, but initial efficacy results were due in the first quarter
and would be made public if clinically meaningful.

Merck said results from a Phase 3 study of MK-7110,
an immune modulator being studied as a treatment
for patients hospitalized with severe COVID-19, were
expected in the first quarter.

Shares of Merck fell 1% to $80.12 in trading before the bell.